If you’ve researched non-surgical body contouring or volume restoration, you’ve probably come across two products that sound very similar: Renuva and alloClae. Both are off-the-shelf injectables made from donated human fat tissue. Both are regulated by the FDA as human cell and tissue products (HCT/Ps). Both restore volume and improve contour without surgery.

But they aren’t the same product, and they aren’t interchangeable. The differences matter and choosing the right one depends on what you’re trying to accomplish.

Here’s a clear breakdown from a board-certified plastic surgeon in Newport Beach.

The fundamental difference: Scaffold vs. Structured tissue

This is the single most important distinction.

Renuva is a decellularized adipose matrix. Donor fat tissue is processed to remove cellular content, leaving behind only the extracellular matrix, which is the scaffolding that fat cells normally live in. When injected, Renuva acts as a structural template. Over the course of three to six months, your body’s own cells migrate into the scaffold, and your own fat regenerates to fill it. The Renuva matrix itself is gradually absorbed and replaced by your native tissue.

alloClae is a structural adipose tissue allograft that preserves both the matrix scaffold and the three-dimensional honeycomb structure of fat tissue, including non-viable intact adipocytes. The cells aren’t living, but the structure is intact, which means alloClae provides immediate volume from the donor adipose tissue itself. Over the following months, your body’s own cells migrate into the matrix as your tissue integrates with the graft.

In simple terms: Renuva is a scaffold that your body fills with your own fat over time. alloClae is structured fat tissue that integrates with your tissue as it settles.

That single mechanical difference explains most of what follows.

alloclae vs renuva_lg

Volume capacity

Renuva is supplied in 1.5 cc and 3 cc syringes which are relatively small volumes. This makes it well-suited for hands, neck, and small contour corrections. For larger body areas, multiple syringes across multiple sessions are typically required, which quickly becomes quite cost-prohibitive.
alloClae is supplied in larger volumes like 12.5 mL and 25 mL packages, with even larger sizes available. It is purpose-built for body contouring applications like hip dips, buttock contouring, breast shaping and post-liposuction corrections.

If your goal involve larger areas of the body, alloClae’s volume capacity is generally the practical choice. For precise work or smaller areas, Renuva’s smaller syringe sizes can be advantageous.

Where each can be used

Renuva is approved for use anywhere natural fat exists in the body, but the manufacturer specifically states that Renuva should not be injected into lips, muscle, or breast tissue.

alloClae can be used in breast revision cases for moderate volume restoration, rippling correction, and contour deformity treatment — making it a useful tool for breast revision patients who want to avoid additional surgery.

For revision breast work specifically, this is a significant practical difference between the two products.

Renuva is a scaffold that your body fills with your own fat over time. alloClae is structured fat tissue that integrates with your tissue as it settles.

Result mechanism and timeline

Renuva: Because Renuva relies on your body filling the matrix with your own fat, results emerge gradually. You won’t see the full effect immediately since the volume develops as native fat regenerates over the course of three to six months. Multiple sessions are often planned, since most clinicians don’t inject to full correction in a single session given the long-lasting nature of the result.

alloClae: Because alloClae provides intact adipose tissue at the time of treatment, you see immediate volume on the day of treatment. The result then settles over three to six months as your tissue integrates with the donor tissue. Single-session results are common for many indications.

If a gradual, regenerative model appeals to you and you’re patient, Renuva fits that mindset. If you want to see the result the day you walk out, alloClae is more appropriate.

Track record and clinical data

Renuva has been on the market longer and has accumulated substantial clinical experience and consumer awareness. It has been featured in mainstream publications and has a longer history of use.

alloClae is newer to the market launched at select practices in 2025. Long-term outcome data is more limited compared with established techniques. Early clinical experience has been positive, but the longer track record currently belongs to Renuva.

For some patients, the longer track record is itself a deciding factor. For others, the practical advantages of alloClae’s mechanism outweigh that consideration.

Renuva vs. alloClae Comparison

Renuva alloClae
Manufacturer MTF Biologics Tiger Aesthetics (Tiger Biosciences)
Composition Decellularized adipose matrix only (acellular scaffold) Structural adipose tissue: ECM plus non-viable intact adipocytes
Mechanism Scaffold that your body fills with your own fat over 3–6 months Immediate volume from donor tissue; integrates with your tissue over 3–6 months
Syringe sizes 1.5 cc and 3 cc 12.5 mL and 25 mL (larger sizes available)
Best applications Hands, neck, small contour corrections Hip dips, buttock contouring, breast revision, post-liposuction correction, larger body work
Time to visible result Gradual — develops over 3–6 months Immediate, then settles over 3–6 months
Track record Longer clinical history and public awareness Newer (launched at select practices in 2025)
Sessions typical Often planned across multiple sessions Often achievable in a single session
FDA regulatory status HCT/P under 21 CFR Part 1271 HCT/P under 21 CFR Part 1271

Finding the right option

RENUVA IS THE BETTER CHOICE WHEN:

• Want a gradual, regenerative approach
• Treating small or precise areas
• Value the longer clinical track record

ALLOCLAE IS THE BETTER CHOICE WHEN:

• Addressing larger body areas (hip dips, buttocks, contour irregularities)
• Want immediate visible volume the day of treatment
• Considering breast revision for rippling or contour issues
• Trying to address volume loss in body areas after weight-loss medications

EITHER MAY WORK WHEN:

• Treating hand volume loss
• Addressing post-liposuction divots or contour irregularities
• Undecided between gradual and immediate results

Why we offer both Renuva and alloClae

If you’re dealing with multiple concerns at once, the way in which they are addressed matters.

My Newport Beach practice offers both products because they aren’t redundant. They’re complementary tools that solve different problems. Choosing between them isn’t a matter of preference. It’s a matter of matching the product’s mechanism to your anatomy, goals, and timeline.

For patients addressing hand rejuvenation, or smaller, precise contour corrections, Renuva is often the better fit. The smaller syringe sizes and gradual, regenerative mechanism suits precise applications.

For patients addressing larger body areas like hip dips, buttock contour, post-liposuction divots or for patients who want to see immediate visible volume the day of treatment rather than wait three to six months for native fat to regenerate, alloClae is generally the better choice. The larger volume capacity and the structured-tissue mechanism make it the more appropriate tool for those applications. alloClae is also the right call when breast revision work is being considered due to the larger available volumes, which also meaningfully impacts cost considerations.

If you are considering non-surgical volume enhancement. Schedule a consult with me to find the right approach based on your specific anatomy and goals.